|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:access_programs
|
available for patients
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:atccode
|
R07 AX
|
|
gptkbp:brand
|
gptkb:Symdeko
|
|
gptkbp:can_be_combined_with
|
gptkb:Ivacaftor
gptkb:Lumacaftor
|
|
gptkbp:casnumber
|
210349-80-5
|
|
gptkbp:chemical_formula
|
C22 H26 F2 N2 O3 S
|
|
gptkbp:class
|
gptkb:Cystic_fibrosis_transmembrane_conductance_regulator_(CFTR)_modulators
|
|
gptkbp:clinical_trial
|
Phase 3
ongoing studies
|
|
gptkbp:clinical_use
|
treatment of cystic fibrosis
|
|
gptkbp:co-administered_with
|
gptkb:Ivacaftor
|
|
gptkbp:collaborations
|
with academic institutions
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
hypersensitivity to tezacaftor
|
|
gptkbp:developed_by
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:drug_interactions
|
CYP3 A inducers
CYP3 A inhibitors
|
|
gptkbp:financial_support
|
available through manufacturers.
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:funding
|
supported by grants
|
|
gptkbp:future_prospects
|
focused on new formulations
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tezacaftor
|
|
gptkbp:indication
|
homozygous F508del mutation
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
pulmonary function tests
liver function tests
|
|
gptkbp:marketed_as
|
gptkb:Symdeko
|
|
gptkbp:mechanism_of_action
|
CFTR modulator
|
|
gptkbp:patient_education
|
important for understanding therapy
|
|
gptkbp:patient_population
|
adults and children over 12
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
CFTR function improvement
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
included in treatment guidelines
|
|
gptkbp:research_focus
|
CFTR modulation
|
|
gptkbp:route_of_administration
|
gptkb:tablet
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:shelf_life
|
2 years
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
nasal congestion
diarrhea
skin rash
elevated liver enzymes
respiratory symptoms
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:support
|
granted in the US
granted in the EU
|
|
gptkbp:targets
|
CFTR protein
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:used_for
|
gptkb:cystic_fibrosis
|
|
gptkbp:weight
|
420.52 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Symdeko
gptkb:CFTR_modulators
|
|
gptkbp:bfsLayer
|
5
|